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Glaucoma is one of the most common causes of blindness in the industrialized
world.
1 The World Health Organization estimates that the global rates of
glaucoma and glaucoma-related disability are above 6.4 million,
1,2 and that by
2020 the number of cases will double to 12 million with an aging population.
1
Glaucoma affects quality of life through visual deterioration as well as through
its treatment, which can require a demanding, lifelong multi-drug regimen.
However, given the asymptomatic nature of the disease, patients are provided
little motivation to maintain this lifelong therapeutic regimen and are at a high risk
of non-adherence.
3
There have been few reports in the literature examining the reasons for poor
adherence with anti-glaucoma medication. None of the common, intuitively
determined factors such as age, gender, level of education, severity of the disease,
and fear of blindness were found to consistently correlate with non-adherence.
4-7
Factors hitherto found to have a correlation with non-adherence include patient’s
knowledge and poor understanding of the disease, increased regimen com-
plexity, and problems in doctor-patient relationships.
8-11 When it comes to ad-
herence issues and psychiatric profiles in the management of glaucoma, per-
sonality structure has been correlated with acceptance of the disease and sub-
sequent cooperation with treatment, while depression has been reported to be
associated with glaucoma.
12,13 Even though there are few studies investigating the
association between the personality of glaucoma patients and their adherence,
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INTRODUCTIONthey are too complicated to apply directly for the routine
clinical setting.
The aim of the present study was to assess patient
attitude towards anti-glaucoma medication and its asso-
ciation with adherence, visual quality of life, and perso-
nality traits.
Participants
The study protocol was approved by the Institutional
Review Board, Severance Hospital, Yonsei University
College of Medicine, Seoul, Korea and adhered to the
tenets of the Declaration of Helsinki. This cross-sectional
study consecutively enrolled 147 confirmed glaucoma
patients who were routinely managed for glaucoma by our
department, or who were referred by primary ophthalmo-
logists to confirm the diagnosis. We excluded patients with
a previous history of acute angle-closure attack and other
ophthalmic conditions that may affect the management of
glaucoma. No participants had a history of psychotic illness,
current alcohol and/or drug abuse, dementia, or had taken
psychoactive drugs prior to the day they were interviewed.
Baseline demographic and clinical information were col-
lected for each participant. 
Modified Glaucoma Drug Attitude Inventory 
(MG-DAI) classification
The drug attitude inventory (DAI) scale was originally
invented for the purpose of categorizing patients taking
anti-psychotic drugs based upon their attitudes towards
medication (pharmacophilic vs. pharmacophobic).
14,15 In
this study, each item of the questionnaire was not only
translated into Korean but was also modified for patients
taking anti-glaucoma medication (Supplement 1). The
item and factorial content, validity, and reliability of the
DAI are described elsewhere.
14 And all questionnaires
were administered by a skilled research assistant.
The Modified Glaucoma Drug Attitude Inventory (MG-
DAI) assigns scores of either +1 (positive attitude) or -1
(negative attitude) to each of the total 30 items, allowing
the score total to range from -30 to  +30. For every patient,
it was ensured that each item was given a score. Those
who had total scores of more than 0 were classified as
“pharmacophilic” and those with negative scores were
classified as “pharmacophobic”.
We grouped the study population according to their
attitude towards medication as presented by the above
MG-DAI. Then, associations of pharmacophilia or phar-
macophobia with the 3 categories listed below were
determined.
Subjective Drug Adherence Score
A subjective adherence score was assessed by asking each
participant during the interview to name the number of
times per week he/she has missed out on the dosing sche-
dule. A grading system was employed from a scale of 1 for
poorest adherence to 5 for best adherence (Supplement 2).
Modified National Eye Institute Visual Functioning
Questionnaire-25 (NEIVFQ-25) for Koreans
The 25-item National Eye Institute Visual Functioning
Questionnaire (NEIVFQ-25) version 2000 is a question-
naire assessing eleven dimensions of visual function and
has been proposed as a means to determine the efficacy of
treatment for different ocular conditions.
16-18 The question-
naire has been translated into many languages, but not yet
into Korean. We therefore translated the original 25 ques-
tions and modified the context into a Korean version (Sup-
plement 3). Due to language constraints and local differ-
ences in culture, the questions were slightly modified.
Myers-Briggs Type Indicator (MBTI) Form GS
The Myers-Briggs Type Indicator (MBTI) is a self-report
form originally developed by Myers and Briggs and tran-
slated into Korean by Sim.
19 It is designed to assess normal
personality traits as a psychometric instrument. This in-
dicator was chosen because it assesses differences that
result from the way people perceive information and how
they prefer to use that information. Individuals fall into
four dichotomous personality dimensions based upon their
scores. There are eight categorical personality types: In-
troversion/Extroversion, Sensing/iNtuition, Thinking/Fee-
ling, and Judging/Perceiving. The validity and reliability of
the Myers-Briggs Type Indicator (MBTI) have been pro-
ven, and the test has been widely used to examine perso-
nality profiles in Korea.
20 The preference scores of the four
dichotomies were used for analysis in the present study.
The patient population was first divided into pharma-
cophobic or pharmacophilic groups as determined by the
MG-DAI as described above. Then, associations between
the above drug attitudes and 1) subjective drug adherence
scores, 2) each sub-category of the Modified NEIVFQ-25,
and 3) each of the 4 personality dichotomies from the
MBTI were sequentially determined.
Statistical analysis
Chi-square tests, Student t-tests, and Mann-Whitney U
tests were used for univariate analyses. And Spearman’s
rank correlation coefficient ( ) was computed to determine
the relationship between MG-DAI and subjective drug
adherence scores. All statistical analyses were carried out
using SPSS 12.0 software (SPSS Inc, Chicago, IL, USA)
for Windows. 
Samin Hong, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 2   March 2010 262
MATERIALS AND METHODSDrug Attitude to Anti-Glaucoma Medication
Yonsei Med J   http://www.eymj.org    Volume 51   Number 2   March 2010 263
Initially, 147 consecutive patients were enrolled in this
study. Of these, 22 patients refused the interview and were
excluded from further analyses. Ten patients declined be-
cause they had an aversion to any clinical study and
another twelve patients declined because they were pressed
for time.
The patients’ demographic characteristics are shown in
Table 1. Ninety-one (72.80%) patients had a ‘pharmaco-
phobic’ attitude and thirty-four (27.20%) showed a ‘phar-
macophilic’ attitude to anti-glaucoma medications. Mean
MG-DAI scores of the pharmacophobic group were -7.42
± 4.39 and those of the pharmacophilic group were 1.74  ±
2.96 (p < 0.001). There were no significant differences
between the two groups for age, gender, number of medi-
cations, disease duration, or visual field indices.
Subjective drug adherence scores were compared using
the Chi-square test (Table 2). As one would predict, the
pharmacophobic group tends to have worse adherence than
the pharmacophilic group. In the pharmacophobic group,
46.15% of patients missed their medication fewer than 1 to
2 times per month, while 70.59% of patients in the phar-
macophilic group showed the same level of adherence.
To investigate the relationship between the MG-DAI
and the subjective drug adherence scores, Spearman’s rank
correlation coefficient ( ) was determined (Fig. 1). Little
association was found between them ( = 0.177, p= 0.049).
Each subscale in the Modified NEIVFQ-25 for Koreans
was compared within the two groups and is shown in
Table 3. No subscale shows a sharp distinction between
the two groups. Although the scores for mental health seem
to be slightly different, it was not statistically significant (p
= 0.115). It revealed that the drug attitude might be not
determined by the patient’s visual function.
Personality dichotomies from the MBTI are shown in
Table 4. In the pharmacophobic group, there were many
more patients with an ‘Introversion’ trait (63.74%) than
with an ‘Extroversion’ trait (36.26%), but the pharmaco-
RESULTS
Table 1.Patient Demographics according to Patient Attitude Towards Anti-Glaucoma Medication
Pharmacophobia Pharmacophilia Comparison of 
pvalue
(n = 91) (n = 34) the two groups
Age (yrs) 57.08 ± 13.69 61.90 ± 13.60 T 0.104
Gender (M : F) 47 : 44 17 : 17 χ 2 0.870
No. of anti-glaucoma medications 1.67 ± 1.00 2.11 ± 1.71 T 0.305
Disease duration (months) 27.59 ± 28.65 33.41 ± 32.29 T 0.510
MD on VF (dB) -8.92 ± 8.56 -10.32 ± 18.65 T 0.616
PSD on VF (dB) 6.26 ± 4.20 5.18 ± 3.84 T 0.105
DAI scores -7.42 ± 4.39 1.74 ± 2.96 Mann-Whitney U < 0.001*
DAI, drug attitude inventory scale; F, female; M , male; MD, mean deviation; PSD, pattern standard deviation; VF, visual field.
*p< 0.05.
Table 2.Subjective Drug Adherence Scores according to Patient Attitude Towards Anti-Glaucoma Medication
Scores
Pharmacophobia Pharmacophilia Comparison of
pvalue
(n = 91) (n = 34) the two groups
1 (miss more than 3 - 4 times/wk) 14 (15.38%) 2 (5.88%)
2 (miss 3 - 4 times/wk) 1 (1.10%) 0 (0.00%)
3 (miss 1 - 2 times/wk) 17 (18.68%) 3 (8.82%) χ 2 0.019*
4 (miss 1  -2 times/month) 17 (18.68%) 5 (14.71%)
5 (miss less than 1 - 2 times/month) 42 (46.15%) 24 (70.59%)
*p< 0.05.
Fig. 1. Relationship between the Modified Glaucoma Drug Attitude Inventory
(MG-DAI) scores and the subjective drug adherence scores.Samin Hong, et al.
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Table 3. Modified National Eye Institute Functioning Questionnaire-25 (NEIVFG-25) Shown for Each Category
according to Patient Attitude Towards Anti-Glau-coma Medication
No. of items
Pharmacophobia Pharmacophilia Comparison of
pvalue
(n = 91) (n = 34) the two groups
General health  1 49.15 ± 22.25 48.28 ± 19.97 Mann-Whitney U 0.806
General vision  2, 3 43.93 ± 25.42 38.36 ± 24.87 Mann-Whitney U 0.280
Ocular pain  4 63.10 ± 26.74 58.33 ± 30.32 Mann-Whitney U 0.441
Near activities  5 - 7 65.04 ± 31.72 59.30 ± 28.96 Mann-Whitney U 0.287
Distance activities 8, 9, 14 64.86 ± 30.91 60.06 ± 31.31 Mann-Whitney U 0.331
Social functioning  11, 13 79.24 ± 25.59 77.16 ± 25.34 Mann-Whitney U 0.660
Mental health  22, 23, 25 84.74 ± 61.59 76.15 ± 29.75 Mann-Whitney U 0.115
Role difficulties  19, 20 66.67 ± 28.74 63.39 ± 27.37 Mann-Whitney U 0.298
Dependency  21, 24 87.93 ± 22.45 89.29 ± 21.24 Mann-Whitney U 0.871
Driving  16 - 18 75.38 ± 28.14 75.00 ± 25.35 Mann-Whitney U 0.649
Color vision  12 83.93 ± 24.12 82.76 ± 23.25 Mann-Whitney U 0.642
Peripheral vision  10 71.88 ± 29.56 65.52 ± 29.44 Mann-Whitney U 0.259
Table 4. Myers-Briggs Type Indicator (MBTI) Profile Shown according to Patient Attitude Towards Anti-
Glaucoma Medication
Pharmacophobia Pharmacophilia Comparison of 
pvalue
(n = 91) (n = 34) the two groups
Extroversion : Introversion
33 : 58 23 : 11
χ
2 < 0.001*
(36.26% : 63.74%) (67.65% : 32.35%)
Sensing : iNtuition
75 : 16 24 : 10
χ
2 < 0.001*
(82.42% : 17.58%) (70.59% : 29.41%)
Thinking : Feeling
72 : 19 18 : 16
χ
2 0.007*
(79.12% : 20.88%) (52.94% : 47.06%)
Judging : Perceiving
59 : 32 29 : 5
χ
2 0.029*
(64.84% : 35.16%) (85.29% : 14.71%)
*p< 0.05.
Table 5. Selected Items of Modified Glaucoma Drug Attitude Inventory (MG-DAI) to Distinguish between 
Pharmacophobic and Pharmacophilic Groups
No. 
Question Answer
of item
2 I feel that the benefits of anti-glaucoma medication outweigh the disadvantages. T F
6 I am fully aware of the pharmacological effects of all of my prescribed medication(s). T F
9 Medication(s) make me feel more relaxed. T F
12 Medication(s) makes me feel tired and sluggish. T F
14 Medications are slow-acting poisons. T F
15 I get along better with people when I am on my medication(s). T F
16 I cannot seem to concentrate on anything when I am taking my medication(s). T F
18 I feel that my eyes are getting better when I am on my medication(s). T F
21 My thoughts are clearer on medication(s). T F
26 I am happier and feel better when I am taking my medication(s). T F
29 I am in better control of myself when I am taking my medication(s). T F
30 By staying on medication(s) I will prevent my eyes from being further damage. T F
F, false; T, true.philic group showed results that were the exact opposite
(Introversion, 32.35%; Extroversion, 67.65%) (p < 0.001).
For both groups, patients tended to be more in the ‘Sensing’,
‘Thinking’, and ‘Judging’ dichotomies than the ‘iNtuition’,
‘Feeling’, and ‘Perceiving’ dichotomies, respectively.
However, component ratios were significantly different. In
the pharmacophobic group, there was a relatively higher
proportion of patients who were Sensing and Thinking and
a relatively lower proportion of patients who were Judging
when compared with the pharmacophilic group. It meant
that the drug attitude might be influenced by the patient’s
personal character.
To select the proper items that help distinguish the two
groups, each item of the MG-DAI was analyzed (Supple-
ment 4). Twelve items (Item No. 2, 6, 9, 12, 14, 15, 16, 18,
21, 26, 29, and 30) showed a clear difference between the
two groups. These selected items are shown in Table 5.
A high rate of non-adherence is prevalent amongst patients
with various chronic medical disorders for which the
benefits of treatment are not immediately apparent.
21-27
Several reports have mentioned that there is no identifiable
type of patient based on demographic or clinical chara-
cteristics that is predictive of compliant behaviour.
3-11 Several
reports have remarked on the influence personality traits
may have on drug adherence issues in chronic medical
conditions.
28-30 Therefore, the purpose of the present study
was to expand on the variables that may possibly be linked
with adherence, with a focus on psychological features that
could lead to better identification of the noncompliant
glaucoma patient.
In a recent study, Pappa, et al.
31 reported on personality
traits and psychiatric profiles of non-compliant glaucoma
patients. They found that a significant proportion of non-
compliant patients with glaucoma (59.5%) were at risk for
psychiatric morbidity and recommended a formal psychia-
tric evaluation. Moreover, they found that depression was
a significant risk factor for non-adherence with glaucoma
treatment. In another report, designed to identify factors
that influence attitudes towards psychopharmacological
treatment in patients diagnosed with schizophrenia, the
authors divided the patients according to their attitude and
attempted to correlate it with adherence issues.
15 This study
was designed, with the aforementioned reports in mind,
specifically for patients with glaucoma.
This report is based on the underlying assumption that a
negative attitude towards pharmacological treatment will
result in decreased adherence. Patients were divided into
two groups based upon their attitude towards pharmacolo-
gical treatment and were given a subjective adherence test.
According to the present study, MG-DAI scores did not
significantly correlate with subjective drug adherence
scores; however, there was a significantly higher proportion
of glaucoma patients who had a negative attitude towards
drugs rather than positive and the greater the patient’s
phobia, the more non-compliant he/she was. The discor-
dance between drug attitude and subjective adherence
implies that at least some patients, even though they had a
negative pharmacological attitude, were still compliant and
vice versa. The rates of non-adherence, however, may
actually be higher because patients are likely to underreport
the times they failed to take their medication when question-
ed.
32-35 And, we should pay attention to the twenty-two
(14.97%) patients who refused any interview because their
personal traits seems to somewhat influence their decision.
The impact of daily visual function on adherence was
measured with the Modified NEIVFQ-25. Each of the
subscales quantified by the questionnaire did not show any
significant correlation with pharmacological adherence.
Only mental health showed potential as a possible distin-
guishing factor between the two groups. 
The possible influence of individual personality traits on
MG-DAI was assessed with the MBTI. There appeared to
be more introverts in the pharmacophobic group. Both
groups had fewer patients who fit into the iNtuition dicho-
tomy than into Sensing, but the phobic group had an even
smaller percentage. Also, there were more patients in the
Thinking dichotomy for both groups, but the phobic group
had a larger percentage than the philic group in this dicho-
tomy. Conversely, although both groups had more patients
in the Judging category, the phobic group had fewer patients
belonging to this category. The question of interpreting
these results by comparing MG-DAI with MBTI needs to
be answered at a later date.
Also, this report attempted to modify the original DAI
questionnaire to suit glaucoma patients, and thus the original
questionnaire was not only interpreted but simplified to
meet these criteria. The authors hereby propose a new,
modified version of the MG-DAI with 12 items (Table 5). 
By introducing a concept of drug attitude, we tried to
make a different approach to adherence in glaucoma pa-
tients. We excluded the patients who had previous ocular
trauma history or received any ocular surgeries to remove
any unexpected impact, but there is a chance that we have
natural selection bias. It is possible that some patients who
were hateful or afraid of medications might already undergo
a certain surgical procedure. This is one limitation of our
study. In addition, many other factors, such as doctor-patient
relationship and patient’s understanding of the disease,
may influence drug attitude and/or adherence. Clinicians
should be concerned with all these things.
Drug Attitude to Anti-Glaucoma Medication
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Supplement 1. Modified Glaucoma Drug Attitude Inventory (MG-DAI) Classification
Name:                                                                ID:
This questionnaire has been prepared for glaucoma patients taking anti-glaucoma medication. The purpose of this
questionnaire is to gather information on your thoughts and experiences with anti-glaucoma medication. The results will
remain within the boundaries of doctor-patient privileges and confidentiality and shall be used only for research purposes
and will not affect the course of your treatment in any way. Please listen to the interviewer and read each question carefully
and circle the answer you feel best represents you. If you feel in any way that you do not wish to partake in this
questionnaire please notify your interviewer now. Thank you for your cooperation. 
In conclusion, according to the results of this study,
pharmacological adherence was influenced by the attitude
towards drugs in general, which was possibly mediated by
an underlying personality trait as revealed by the MBTI.
However, because the present study is limited due to its
usage of a subjective adherence test,
32-35 which can also be
influenced by personality traits, another study needs to be
done using methods that objectively quantify adherence to
drugs. The assessment of those patients who refused to
participate in an interview will be addressed in the future. 
Presented at the 8th Congress of European Glaucoma
Society, June 1-6, 2008, Berlin, Germany.
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SUPPLEMENT
1. I do not feel the need for additional medication once I feel my condition has improved. T F
2. I feel that the benefits of anti-glaucoma medication outweigh the disadvantages. T F
3. If I am feeling strange, I do not use my prescribed medication(s). T F
4. I stick to a regular medical routine, even though I am months away from my next visit. T F
5. If I take the medication, it’s only because of peer pressure. T F
6. I am fully aware of the pharmacological effects of all of my prescribed medication(s). T F
7. Taking medication will do me no harm. T F
8. I take medications of my own accord. T F
9. Medication(s) make me feel more relaxed. T F
10. I am no different on or off medication(s). T F
11. The unpleasant effect(s) of medication(s) are always present. T F
12. Medication(s) makes me feel tired and sluggish. T F
13. I take medication only when I feel ill. T F
14. Medications are slow-acting poisons. T F
15. I get along better with people when I am on my medication(s). T F
16. I cannot seem to concentrate on anything when I am taking my medication(s). T F
17. I know better than the doctors when to stop taking my medication(s). T F
18. I feel that my eyes are getting better when I am on my medication(s). T F
19. I would rather let my eyes suffer than take my medication(s). T F
20. Taking medication(s) is an unnatural act. T F
21. My thoughts are clearer on medication(s). T F
22. I should keep taking medication(s) even when my eyes feel well. T F
23. Taking medication(s) will ultimately be beneficial for my eyes. T F
24. It is up to the doctor to decide when I should stop taking my medication(s). T F
25. Things that I could do easily are much more difficult when I am on medication(s). T F
26. I am happier and feel better when I am taking my medication(s). T F
27. I take my medication(s) because other people dislike it if I do not. T F
28. I cannot relax on my medication(s). T F
29. I am in better control of myself when I am taking my medication(s). T F
30. By staying on medication(s) I will prevent my eyes from being further damaged. T FDrug Attitude to Anti-Glaucoma Medication
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Supplement 3. Modified National Eye Institute Visual Functioning Questionnaire-25 (NEIVFQ-25) for Koreans
Name: ID  :
1. In general, would you say your overall health is:
A. Excellent       B. Very Good       C. Good       D. Fair       E. Poor
2. At the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is:
A. Excellent       B. Very Good       C. Good       D. Fair       E. Poor
3. How much of the time do you worry about your eyesight?
A. None of the time       B. A little of the time       C. Some of the time       D. Most of the time       E. All of the time
4. How much pain or discomfort have you had in and around your eyes (for example, burning, itching, or aching)? 
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
5. How much difficulty do you have reading ordinary print in newspapers? 
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
6. How much difficulty do you have doing work or hobbies that require you to see well up close, such as cooking,
sewing, fixing things around the house, or using hand tools? 
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
7. Because of your eyesight, how much difficulty do you have finding something on a crowded shelf?
A. None       B. Mild       C. Moderate       D. Sever         E. Very severe
8. How much difficulty do you have reading street signs or the names of stores?
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
9. Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night?
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
10. Because of your eyesight, how much difficulty do you have noticing objects off to the side while you are walking along?
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
11. Because of your eyesight, how much difficulty do you have seeing how people react to things you say?
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
12. Because of your eyesight, how much difficulty do you have picking out and matching your own clothes?
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
13. Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in
restaurants?
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
14. Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events?
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
15. Now, I’d like to ask about driving a car. 
A. I have never driven a car. (�Skip To Q 19)
B. I have given up driving. Was that mainly because of your eyesight, mainly for some other reason, or because of
both your eyesight and other reasons? (� Skip To Q 19)
i. Mainly eyesight       ii. Mainly other reasons       iii. Both eyesight and other reasons 
C. I am currently driving.
16. How much difficulty do you have driving during the daytime in familiar places?
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
17. How much difficulty do you have driving at night? 
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
18. How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the
Supplement 2. Grading System of Subjective Drug Adherence Scores
Score Frequency of missed drug schedule(s)
1 More than 3 - 4 times per wk
2 3 - 4 times per wk
3 1 - 2 times per wk
4 1 - 2 times per month
5 Less than 1-2 times per monthSamin Hong, et al.
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freeway, or in city traffic?
A. None       B. Mild       C. Moderate       D. Severe       E. Very severe
19. Do you accomplish less than you would like because of your vision?
A. None of the time       B. A little of the time       C. Some of the time       D. Most of the time       E. All of the time
20. Are you limited in how long you can work or do other activities because of your vision?
A. None of the time       B. A little of the time       C. Some of the time       D. Most of the time       E. All of the time
21. I stay home most of the time because of my eyesight.
A. Definitely false       B. Mostly false       C. Not sure       D. Mostly true       E. Definitely true
22. I feel frustrated a lot of the time because of my eyesight.
A. Definitely false       B. Mostly false       C. Not sure       D. Mostly true       E. Definitely true
23. Because of my eyesight, I have to rely too much on what other people tell me. 
A. Definitely false       B. Mostly false       C. Not sure       D. Mostly true       E. Definitely true
24. I need a lot of help from others because of my eyesight.
A. Definitely false       B. Mostly false       C. Not sure       D. Mostly true       E. Definitely true
25. I worry about doing things that will embarrass myself or others, because of my eyesight.
A. Definitely false       B. Mostly false       C. Not sure       D. Mostly true       E. Definitely true
Supplement 4. Difference of Each Items of Modified Glaucoma Drug Attitude Inventory (MG-DAI)
between Pharmacophobic and Pharmacophilic Groups
No. of MG-DAI χ
2 df p value
1 0.240 1 0.624
2 11.520 1 0.001*
3 0.002 1 0.967
4 0.537 1 0.464
5 0.642 1 0.423
6 5.204 1 0.023*
7 2.494 1 0.114
8 0.284 1 0.594
9 15.629 1 < 0.001*
10 2.067 1 0.150
11 3.180 1 0.075
12 6.089 1 0.014*
13 1.800 1 0.180
14 5.140 1 0.023*
15 24.359 1 < 0.001*
16 4.064 1 0.044*
17 0.059 1 0.808
18 16.962 1 < 0.001*
19 0.086 1 0.769
20 0.039 1 0.844
21 33.107 1 < 0.001*
22 0.589 1 0.443
23 0.086 1 0.769
24 1.094 1 0.296
25 3.400 1 0.065
26 21.448 1 < 0.001*
27 1.290 1 0.256
28 0.059 1 0.808
29 25.973 1 < 0.001*
30 7.902 1 0.005*
*p< 0.05.Drug Attitude to Anti-Glaucoma Medication
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